FIND A CENTER NEAREST YOU:

Our first-generation product and next-generation technology have enabled patients to resume normal lives with their families, occupations, and hobbies.

WorldHeart Corporation is:

developing innovative, implantable next-generation heart assist pumps such as the continuously pumping, hockey-puck size Levacor™ VAD for adults who suffer from late-stage heart failure. Designed to provide long-term and full circulatory support, the Levacor VAD is powered by a revolutionary and proprietary magnetic levitation technology. We anticipate starting a US clinical trial in the 2nd half of 2009 to assess the Levacor VAD as a bridge to heart transplant.
also developing two miniaturized implantable pumps, each the size of a AA battery: 1) a MIVAD™ for adults with earlier-stage heart failure who need long-term partial cardiac support. The MIVAD is derived from 2) the Pediaflow™ VAD for newborns and infants with congenital heart defects and other heart ailments that need cardiac support of up to 6 months. The PediaFlow VAD has been developed since 2004 with support from the U.S. National Institutes of Health.
building on the foundation of more than two decades of supporting heart failure patients with the pioneering first-generation Novacor® LVAS: one of only two such electrically-powered pulsatile pumps commercialized in North America, Europe and Japan. Distribution of this device was discontinued in 2008 as our focus shifted to the next-generation Levacor VAD. The legacy of this pulsatile assist pump has been to provide circulatory support to more than 1,800 heart failure patients both as a bridge to heart transplant, and as an alternative to heart transplant. It increased recipients' survival on the device by more than 6 years in one case.
headquartered in Salt Lake City, Utah with additional facilities in Oakland, California and in Herkenbosch, the Netherlands.

THAT'S WORLDHEART... TECHNOLOGY for LIFE